Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer-Reference-Cited by-同舟云学术

Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer

Published:2023-11-24 Issue: Volume: Page:
ISSN:1073-6085
Container-title:Molecular Biotechnology
language:en
Short-container-title:Mol Biotechnol

Author:

Xing Zhiwei,Gao Yanan,Shi Yaxuan,Gao Ziyu,Liu Caixia^ORCID

Funder

Inner Mongolia Medical University “Zhiyuan Talent Program”

Health Commission of Inner Mongolia Autonomous Region Health Medical and Health Science and Technology Project 2022

Affiliated Hospital Inner Mongolia Medical University Scientific Research Project

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,Bioengineering,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s12033-023-00966-x.pdf

Reference46 articles.

1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249.

2. Joshi, S. S., & Badgwell, B. D. (2021). Current treatment and recent progress in gastric cancer. CA: A Cancer Journal for Clinicians, 71, 264–279.

3. Zhang, T., Wang, B., Su, F., Gu, B., Xiang, L., Gao, L., Zheng, P., Li, X. M., & Chen, H. (2022). TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. International Journal of Biological Sciences, 18, 4560–4577.

4. Song, Z., Wu, Y., Yang, J., Yang, D., & Fang, X. (2017). Progress in the treatment of advanced gastric cancer. Tumour Biology, 39, 1010428317714626.

5. Ryu, M. H., & Kang, Y. K. (2009). ML17032 trial: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Review of Anticancer Therapy, 9, 1745–1751.